COVID-19 vaccine: Russia all set to approve second vaccine n
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Russia is all set to register its second coronavirus vaccine next week, vaccine developer's said on 9 October, according to Reuters report.

Developed by Vector State Research Center of Virology and Biotechnology, the experimented vaccine has recently completed its early-stage human trials.

The Vector Research Center obtained the Russian Health Ministry’s permit to conduct clinical trials of its vaccine on volunteers in July.

The first volunteer was injected with the vaccine on July 27. The final group of 20 volunteers was discharged from the medical facility on September 8, according to TASS report.

They will begin Phase III trials in November-December, the TASS news agency cited Russian consumer safety watchdog Rospotrebnadzor.

Nearly 30,000 volunteers will take part in post-registration trials of the coronavirus vaccine, the press service of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing told TASS.

Russia had in August approved a COVID vaccine, named Sputnik V, even before its final trial. The vaccine is currently undergoing final trials in Russian around 40,000 subjects. Sputnik V has been developed by the Gamaleya National Research Center of Epidemiology and Microbiology and RDIF.

Indian pharma company Dr Reddy's has collaborated with the Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V vaccine as well as for its distribution.

Dr. S●●●●●●●●i K●●●●●o and 5 others like this